Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$28K Buy
18,100
+6,400
+55% +$20.5K ﹤0.01% 7545
2014
Q2
$40K Sell
11,700
-3,200
-21% -$11K ﹤0.01% 7157
2014
Q1
$53K Buy
14,900
+1,900
+15% +$12.9K ﹤0.01% 6748
2013
Q4
$80K Buy
13,000
+12,300
+1,757% +$67.8K ﹤0.01% 6345
2013
Q3
$4K Sell
700
-19,100
-96% -$98.8K ﹤0.01% 9559
2013
Q2
$90K Buy
+19,800
New +$93.8K ﹤0.01% 6037

Other funds holding EXEL

UBS's EXEL Position: Q3 2014 in Review

UBS increased its Exelixis (EXEL) stake by 1.6% in Q3 2014, buying an estimated $3.43K and bringing the position to 69,772 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #5916.

UBS first reported a position in EXEL in Q2 2013 and has held it in 6 quarters since. The position peaked at $242K in Q2 2013. 125 funds tracked by Wall St. Rank hold EXEL as of Q3 2014.

  • UBS held 69,772 shares of Exelixis worth $107K as of Q3 2014.
  • UBS bought 1,070 Exelixis shares in Q3 2014, an estimated $3.43K.
  • Exelixis made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5916 holding.
  • UBS first reported a position in Exelixis in Q2 2013 and has held it in 6 quarters since.
  • UBS's Exelixis position peaked at $242K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Exelixis as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.